We previously reported in preclinical murine models of diabetes, two-week administration of Interleukin-22 (IL-22) directly suppressed β-cell oxidative and endoplasmic reticulum (ER) stress, reduced local islet inflammation, restored appropriate insulin production, reversed hyperglycemia and ameliorated insulin resistance5. The gene discussed is IL22; the disease is diabetes mellitus.